We are focused on continued innovation to broaden our Labyrinthin based platform through internal research and collaboration with leading academic institutions and strategic industry partners in the field of immunology.

Because available data collectively indicate that Labyrinthin is a promising therapeutic target for adenocarcinomas regardless of tissue origins, several therapeutic strategies targeting Labyrinthin are under development, including vaccines against Labyrinthin.